N.n. Alexandrov National Cancer Centre

This study tests a combination of immunotherapy drugs (PD-1/PD-L1 inhibitors) with chemotherapy, with or without bevacizumab, in 120 adults with metastatic, persistent, or recurrent cervical cancer. The goal is to see if this approach helps patients live longer and controls the d…

This study is testing a more affordable version of CAR-T cell therapy for people with relapsed or hard-to-treat large B-cell lymphoma. The treatment uses the patient's own immune cells, modified to attack cancer cells. The goal is to see if this academic-made therapy works as wel…

This study tests whether a PARP inhibitor combined with bevacizumab (Avastin) can delay cancer recurrence in people with advanced ovarian, fallopian-tube, or primary peritoneal cancer that has a specific DNA repair defect (HRD). About 120 participants will receive chemotherapy pl…

This study is testing whether removing fewer lymph nodes during prostate cancer surgery is as safe and effective as removing more. Researchers will compare two groups of 800 men with prostate cancer who are having their prostate removed. One group will have a limited lymph node r…